|
Tunlametinib Clinical Trials
4 actively recruiting trials
▲ +1 trial since August 2026
Pipeline
Phase 2: 3Phase 3: 1
Top Sponsors
- Tianjin Medical University Second Hospital1
- Sun Yat-sen University1
- Shanghai Kechow Pharma, Inc.1
- Fudan University1
Indications
- Cancer4
- NRAS Mutation1
- Advanced PDTC or ATC With NRAS Mutation1
- Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation1
- Melanoma Metastatic1
Other4 trials
Phase 3
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.